Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24036831 | 0.83 | HPGD (0.39) | MAPTHPGDL3MBTL1ALDH1A1ATM | |
| SCHEMBL25624042 | 0.83 | MAPT (0.44) | MAPTHPGDL3MBTL1ALDH1A1KAT6A | |
| SCHEMBL25754244 | 0.80 | LMNA (0.47) | KAT6ADGAT2WDR5TACR3 | |
| SCHEMBL25753682 | 0.79 | MAPT (0.38) | MAPTHPGDL3MBTL1ALDH1A1KAT6A | |
| SCHEMBL24036983 | 0.79 | MAPT (0.38) | MAPTHPGDL3MBTL1ALDH1A1KAT6A | |
| SCHEMBL28709399 | 0.76 | SMYD3 (0.41) | MAPTHPGDL3MBTL1ALDH1A1KAT6A | |
| SCHEMBL28698405 | 0.76 | SMYD3 (0.41) | MAPTHPGDL3MBTL1ALDH1A1KAT6A | |
| SCHEMBL24036552 | 0.76 | CYP3A4 (0.46) | MAPTALDH1A1POLB | |
| SCHEMBL28699688 | 0.76 | ITGAV (0.39) | MAPTHPGDL3MBTL1TDP1 | |
| SCHEMBL24036731 | 0.76 | WDR5 (0.50) | HPGDALDH1A1WDR5TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | UBE CORPORATION (JP) | 2023-06-22 | — | — | US | disclosed |
| WO-2023085396-A1 | PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME | ＵＢＥ株式会社 | 2023-05-19 | — | — | WO | disclosed |
| WO-2021230325-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | 宇部興産株式会社 | 2021-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192661-A1 | 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE | DHFR, DPYD, CYP2D6 | MAPT 3157/4885HPGD 1458/4885L3MBTL1 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.